These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36808072)

  • 1. De-escalation treatment with pasireotide for acromegaly: a long-term experience.
    Giampietro A; Menotti S; Chiloiro S; Pontecorvi A; De Marinis L; Bianchi A
    Endocrine; 2023 Jun; 80(3):505-510. PubMed ID: 36808072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of 6 Months' Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings.
    Witek P; Bolanowski M; Szamotulska K; Wojciechowska-Luźniak A; Jawiarczyk-Przybyłowska A; Kałużny M
    Front Endocrinol (Lausanne); 2021; 12():633944. PubMed ID: 33776927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
    Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
    BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
    Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
    J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
    Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A
    Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of long-acting pasireotide in acromegaly.
    Akirov A; Gorshtein A; Dotan I; Khazen NS; Pauker Y; Gershinsky M; Shimon I
    Endocrine; 2021 Nov; 74(2):396-403. PubMed ID: 34081309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.
    Schmid HA; Brue T; Colao A; Gadelha MR; Shimon I; Kapur K; Pedroncelli AM; Fleseriu M
    Endocrine; 2016 Jul; 53(1):210-9. PubMed ID: 26906713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
    Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
    Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
    Chang JS; Tseng HM; Chang TC
    J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pasireotide: a novel treatment for patients with acromegaly.
    Cuevas-Ramos D; Fleseriu M
    Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
    Chiloiro S; Giampietro A; Mirra F; Donfrancesco F; Tartaglione T; Mattogno PP; Angelini F; Liverana L; Gessi M; Carmelo A; Rindi G; Giustina A; Fleseriu M; Pontecorvi A; De Marinis L; Bianchi A
    Eur J Endocrinol; 2021 Feb; 184(2):217-229. PubMed ID: 33136550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide: potential treatment option for McCune-Albright-associated acromegaly.
    Ilie MD; Raverot G; Brac de la Perrière A
    Eur J Endocrinol; 2024 Jan; 190(1):K17-K20. PubMed ID: 38128124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
    Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
    J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
    Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
    Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation.
    Stelmachowska-Banaś M; Czajka-Oraniec I; Tomasik A; Zgliczyński W
    Pituitary; 2022 Feb; 25(1):180-190. PubMed ID: 34498217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Position Pasireotide LAR Treatment in Acromegaly.
    Coopmans EC; Muhammad A; van der Lely AJ; Janssen JAMJL; Neggers SJCMM
    J Clin Endocrinol Metab; 2019 Jun; 104(6):1978-1988. PubMed ID: 30608534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers.
    Tauchmanova L; Breitschaft A; Holder G; Han KT; Choudhury S; Darstein C; Paul M; Drutinus E; Gericke G; Schmid HA; Pedroncelli AM
    Endocrine; 2022 Feb; 75(2):537-548. PubMed ID: 34741720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.